EA201891895A1 - ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЙ β-АРРЕСТИНА С РЕЦЕПТОРОМ НЕЙРОКИНИНА 1 ДЛЯ ЛЕЧЕНИЯ БОЛИ - Google Patents

ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЙ β-АРРЕСТИНА С РЕЦЕПТОРОМ НЕЙРОКИНИНА 1 ДЛЯ ЛЕЧЕНИЯ БОЛИ

Info

Publication number
EA201891895A1
EA201891895A1 EA201891895A EA201891895A EA201891895A1 EA 201891895 A1 EA201891895 A1 EA 201891895A1 EA 201891895 A EA201891895 A EA 201891895A EA 201891895 A EA201891895 A EA 201891895A EA 201891895 A1 EA201891895 A1 EA 201891895A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pain
treatment
arrestine
neurokinin
interactions
Prior art date
Application number
EA201891895A
Other languages
English (en)
Other versions
EA038338B1 (ru
Inventor
Найджел Баннет
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900635A external-priority patent/AU2016900635A0/en
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201891895A1 publication Critical patent/EA201891895A1/ru
Publication of EA038338B1 publication Critical patent/EA038338B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям и их применению, в частности к соединениям, которые ингибируют взаимодействие между β-аррестином и внутриклеточным C-концом активированного NKR, и к их применению при лечении боли.
EA201891895A 2016-02-23 2017-02-23 Ингибиторы взаимодействий -аррестина с рецептором нейрокинина 1 для лечения боли EA038338B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016900635A AU2016900635A0 (en) 2016-02-23 Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain
PCT/AU2017/050158 WO2017143397A1 (en) 2016-02-23 2017-02-23 INHIBITORS OF β-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN

Publications (2)

Publication Number Publication Date
EA201891895A1 true EA201891895A1 (ru) 2019-02-28
EA038338B1 EA038338B1 (ru) 2021-08-11

Family

ID=59684698

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891895A EA038338B1 (ru) 2016-02-23 2017-02-23 Ингибиторы взаимодействий -аррестина с рецептором нейрокинина 1 для лечения боли

Country Status (9)

Country Link
US (1) US20200206299A1 (ru)
EP (1) EP3419644A4 (ru)
JP (2) JP2019509277A (ru)
AU (1) AU2017223226A1 (ru)
CA (1) CA3015545A1 (ru)
EA (1) EA038338B1 (ru)
MA (1) MA43801A (ru)
MX (1) MX2018010174A (ru)
WO (1) WO2017143397A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870236B1 (en) * 2018-10-22 2023-08-09 Takeda Pharmaceutical Company Limited Nanoparticle encapsulation to target g protein-coupled receptors in endosomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016547A1 (en) * 1991-03-15 1992-10-01 The Children's Medical Center Corporation Controlling nk-1 receptor-mediated responses and related diagnostics
PT1218494E (pt) * 1999-09-22 2005-08-31 Canbas Co Ltd Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn
ES2552587B1 (es) * 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Also Published As

Publication number Publication date
MX2018010174A (es) 2019-01-10
WO2017143397A1 (en) 2017-08-31
CA3015545A1 (en) 2017-08-31
EP3419644A1 (en) 2019-01-02
AU2017223226A1 (en) 2018-08-30
JP2022064920A (ja) 2022-04-26
US20200206299A1 (en) 2020-07-02
EA038338B1 (ru) 2021-08-11
MA43801A (fr) 2018-11-28
EP3419644A4 (en) 2019-11-13
JP2019509277A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
EA202090655A1 (ru) Комбинированные терапевтические средства и их применение
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790380A1 (ru) Ингибиторы mk2 и их применения
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790434A1 (ru) Модуляторы каналов
MX2018008939A (es) Anticuerpos anti-factor de la coagulacion xi.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
EA201592203A1 (ru) Способы лечения таупатии
TN2018000417A1 (en) Anti-coagulation factor xi antibodies.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201791467A1 (ru) Водный офтальмологический раствор
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение